Thermo Fisher, Newomics ink disease biomarker validation partnership

The companies will look to develop and optimize microflow LC-MS solutions which could advance the understanding and diagnosis of complex diseases

Leading biotechnology company Thermo Fisher Scientific has recently confirmed it will collaborate with Newomics, a firm that supplies microfluidic emitters applicable in liquid chromatography-mass spectrometry (LC-MS).

Apparently, the partnership is aimed at developing and optimizing robust, sensitive microflow LC-MS workflows that are reproducible, by combining the innovative technologies and expertise offered by both the companies, for disease biomarker validations.

According sources with knowledge on the matter, nanoflow chromatography restricts the speed of analysis and also makes it difficult to maintain performance consistently in extended studies. However, microflow LC-MS allows for a balance of speed, throughput and sensitivity for the discovery and validation of biomarkers in translational proteomic labs.

The partnership would reportedly combine the microflow LC-MS systems and the Nanospray Flex ion source from Thermo Fisher with the multi-nozzle emitters from Newomics, for achieving nanospray flowrate benefits along with the enhanced robustness and throughput of microflow LC-MS.

Newomics Founder and CEO, Daojing Wang said that the combination of the company’s unique emitters and Thermo Fisher’s expertise in microflow LC-MS would help improve workflow selectivity and sensitivity. This would assist scientists in detecting even low-abundance analytes in blood, urine and other clinically relevant samples, he explained.

Wang believes working with Newomics will allow the development and optimization of microflow LC-MS solutions which could advance further the understanding and diagnosis of complex diseases.

Emily Chen, Thermo Fishers senior director for Precision Medicine Science Center commented that validation workflows which enable sensitive, rapid and high-throughput analysis to process large quantity of samples are needed to translate advanced biomarker discoveries into applications that are clinically meaningful. 

Chen added that collaborating with Newomics is primarily aimed at providing greater sensitivity and reproducibility, for supporting the growing demand for high-throughput analysis from the firm’s clinical research clients, using microflow LC-MS analysis.

Source Credit: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-announces-collaboration-with-newomics-to-advance-disease-biomarker-validation-300860476.html